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Introduction: There has been little work on the relationship between sarcopenia, a progressive skeletal muscle
disorder, and age-related neurodegenerative diseases such as Parkinson's disease (PD).
Objectives: We aimed to determine: 1) the feasibility of characterizing skeletal muscle across a range of cognitive
function in PD; 2) if muscle mitochondrial respiratory chain (MRC) function and content are preserved in older
adults with PD.
Methods: Sarcopenia was defined using handgrip strength, chair rise and bioimpedance analysis. MRC function
was assessed using phosphorous magnetic resonance spectroscopy (MRS) by estimating τ1/2 PCr (s) (phospho-
creatine half-time recovery) in the calf muscles following a bout of aerobic exercise. Biopsy of the vastus lateralis
muscle was performed, and MRC content assessed by fluorescent immunohistochemistry for porin and com-
ponents of MRC Complexes I and IV.
Results: Nine participants (78% male; mean age 79.9; PD duration 3.3 years) were recruited. Four had cognitive
impairment. Six participants had probable sarcopenia. Eight participants completed MRS and had mean (SD) τ1/
2 PCr of 37.8 (7.6) seconds, suggesting preserved mitochondrial function. Muscle biopsies were obtained in all
and the procedure was well tolerated. Porin Z-score, a proxy for mitochondrial mass, was lower than expected
compared to controls (0–89% of fibres with low porin). There was a small amount of Complex I (0.16–4.59%)
and Complex IV (0–3.79%) deficiency.
Conclusions: Detailed phenotyping, muscle biopsy and imaging was feasible and acceptable across a spectrum of
cognitive function in PD. Sarcopenia was relatively common and may be associated with lower mitochondrial
mass and low levels of MRC deficiency.
1. Introduction
The prevalence of Parkinson's disease (PD) and thus the burden of
its associated symptoms will increase in future years due to secular
trends in the age-structure of populations (GBD 2016 Parkinson's
Disease Collaborators, 2018). Optimizing health in older age is there-
fore of utmost importance in terms of health and social care costs and
prevention of morbidity and mortality associated with the disease. An
understanding of the mechanisms which govern both healthy and ad-
verse aging in PD would permit the more effective use of interventions
in the disorder.
Sarcopenia, a progressive and generalized muscle disorder with
accelerated loss of muscle strength and mass (Cruz-Jentoft et al., 2019;
Cruz-Jentoft and Sayer, 2019) leading to impaired function (Cruz-
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Jentoft et al., 2019; Cruz-Jentoft and Sayer, 2019; Cruz-Jentoft et al.,
2010), is a major focus for translational research, and is most frequent
in older age groups (Cruz-Jentoft et al., 2014; Dodds et al., 2017). Its
identification is of vital importance due to the association with adverse
health outcomes (Beaudart et al., 2017) and strong evidence base for
resistance exercise in its primary treatment (Dent et al., 2018). To date,
there has been a paucity of work on how sarcopenia may interrelate to
age-related neurological diseases such as PD. Preliminary work suggests
that accelerated muscle loss may start early in the neurodegenerative
disease process, with an association highlighted between early stage
sarcopenia and motor dysfunction in a prodromal PD cohort (Drey
et al., 2017). This is supported by earlier work demonstrating that low
handgrip strength, a key parameter of sarcopenia in the revised Eur-
opean Working group on Sarcopenia in Older People (EWGSOP2)
guidelines (Cruz-Jentoft et al., 2019), is associated with increasing se-
verity of PD (Roberts et al., 2015). Studies in established PD have found
a higher prevalence of sarcopenia than controls (Peball et al., 2019; Tan
et al., 2018), although lacked the extensive phenotyping to elicit po-
tential underlying neurobiological mechanisms.
There is good evidence that bioenergetic abnormalities exist in PD;
in this context, mitochondrial dysfunction is of particular importance.
Neurons are reliant on mitochondrial integrity and have high rates of
metabolic activity, especially in presynaptic and postsynaptic sites
(Exner et al., 2012). Mitochondrial dysfunction has also been im-
plicated in the development of sarcopenia (Brierley et al., 1996; Joseph
et al., 2012; St-Jean-Pelletier et al., 2017), although recent work found
preservation of muscle mitochondrial respiratory chain (MRC) function
and content in healthy, active 85-year-olds (Dodds et al., 2018). A
number of historic studies have demonstrated mitochondrial abnorm-
alities in PD in non-neuronal tissue (Bindoff et al., 1991; Blin et al.,
1994; Ercan et al., 2009), but the role of skeletal muscle mitochondrial
abnormalities in PD in relation to sarcopenia or physical performance
has not yet been evaluated.
In view of the absence of mechanistic studies of older patients with
PD where detailed phenotyping, muscle biopsy and imaging are ana-
lyzed, the aims of this study were to determine: 1) the feasibility of
obtaining and characterizing muscle in older adults with PD, including
phosphorous magnetic resonance spectroscopy (31P-MRS) and skeletal
muscle biopsy; and 2) if skeletal muscle MRC chain function and con-
tent are preserved in those with and without sarcopenia across a range
of cognition.
2. Methods
2.1. Participants and assessments
Participants with PD, diagnosed by a movement disorder specialist
according to the Queen Square Brain Bank criteria (Hughes et al.,
2002), and stable on current medication for a minimum of four weeks
were recruited from the Newcastle upon Tyne NHS Foundation Trust
Parkinson's service. Exclusion criteria comprised individuals with a
cardiac pacemaker in situ or any other metallic or programmable de-
vice; those unable to give informed consent; those taking anticoagulant
or antiplatelet drugs that were unable to be temporarily stopped; and
those considered inappropriate to approach according to their treating
clinician. All participants had capacity to provide written informed
consent, and the study was approved by the Tyne & Wear South Re-
search Ethics Committee (17/NE/0150), UK and conformed to the
principles of the Declaration of Helsinki.
General demographic data including disease duration, past medical
history and current medication (including levodopa equivalent daily
dose (LEDD; mg/day) (Tomlinson et al., 2010) were obtained from
participants. Motor function was evaluated using the Movement Dis-
order Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
(Goetz et al., 2008), mood was assessed with the 15-item Geriatric
Depression Scale (GDS) (Yesavage et al., 1982), and global cognition
with the Mini-Mental State Examination (MMSE) (Folstein et al., 1975)
and Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005)
tools. Participants were defined as having normal cognition, mild
cognitive impairment (PD-MCI; based on Level I Movement Disorder
Society criteria (MoCA<26/30 plus decline noted by participants/fa-
mily/treating clinician with no evidence of impact on activities of daily
living (ADLs) (Litvan et al., 2012), or mild PD dementia (PDD; ac-
cording to Movement Disorder Society Task Force Criteria for PDD)
(Emre et al., 2007). Self-reported difficulties or needing help with 17
ADLs such as dressing/undressing, cutting toenails, shopping and
managing finances was enquired from participants. The Short Form 36
(SF-36) Health Survey Questionnaire was used to derive general health
and physical functioning scores (Ware Jr. and Gandek, 1998). Self-re-
ported physical activity was assessed using the rapid assessment of
physical activity (RAPA), deriving scores for aerobic activity (1–7, with
7 being most active) and strength and flexibility activity (0–3, with 3
most being active) (Topolski et al., 2006). Height and weight were used
to calculate body mass index (BMI). Ambulatory activity was objec-
tively measured in the home using body worn sensors using the vali-
dated Axivity movement sensor (AX3; Axivity, York, UK; 100 Hz,± 8
g), with a sampling frequency of 100 Hz. Outcomes measured for ac-
celerometry data were in keeping with previous work (Lord et al.,
2013).
2.2. Identifying sarcopenia
Handgrip strength (kg) was measured with a Jamar handheld hy-
draulic dynamometer (Promedics, UK) using three trials in both hands
following a standard protocol (Roberts et al., 2011) and using the
maximum value obtained for analyses. Chair stand test (5-times sit-to-
stand) and 4-meter gait speed (m/s) were also measured using stan-
dardized protocols. Assessments were performed whilst “on” medica-
tion. Height (cm), body weight (kg) and bioimpedance were assessed
using TANITA TBF-300 MA (TANITA Corporation, Tokyo, Japan).
Whole body impedance (R; ohms) was used to estimate skeletal muscle
(SM) mass using the formula: SM mass (kg) = [(Ht2/
R× 0.401) + (gender × 3.825) + (age ×−0.071)] + 5.102 (Janssen
et al., 2000). Skeletal muscle index (SMI; kg/m2) was calculated from
SM mass divided by height squared, with a cut-off as≤10.75 kg/m2 in
men and ≤6.75 kg/m2 in women considered as low lean mass (Cruz-
Jentoft et al., 2010).
Probable sarcopenia was defined using the EWGSOP2 guidelines:
handgrip strength< 27 kg in men or< 16 kg in women, and/or chair
stand> 15 s for five rises (Cruz-Jentoft et al., 2019). Confirmed sar-
copenia was present in participants who also had low SMI, and severe
sarcopenia in those who also had both low SMI and a gait speed
≤0.8 m/s.
2.3. Phosphorous magnetic resonance spectroscopy
Participants attended 31P-MRS scanning and performed a low-in-
tensity plantar flexion exercise in the scanner with incremental loading,
until the phosphocreatine in the gastrocnemius and soleus muscles was
depleted by approximately 50%. Measurements were taken every 10 s
during exercise and recovery. An exponential recovery curve was fitted
to the area under the phosphocreatine peak from which we modelled
the time taken, τ1/2 PCr (seconds), for recovery halfway to baseline, as a
measure of mitochondrial oxidative function, with shorter times im-
plying higher function (Hollingsworth et al., 2008).
2.4. Muscle biopsy
Biopsy of the vastus lateralis muscle was obtained under local an-
aesthesia from all participants using a Weil Blakesley conchotome. The
samples were snap frozen in isopentane cooled in liquid nitrogen.
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2.5. Quadruple immunofluorescence
Two 10 μm sections from each biopsy were used for the quadruple
immunofluorescence with antibodies to laminin, NDUFB8 (subunit of
Complex I), MTCOI (subunit of Complex IV) and porin, as described
previously (Dodds et al., 2018; Rygiel et al., 2017). Control samples
were biopsies obtained from three younger patients undergoing or-
thopaedic surgery (males aged 20 and 24; female aged 23 years). The
control and participant sections were reacted the same day with the
same batch of antibody and identical concentrations. All exposure times
were set and maintained throughout the imaging.
The immunofluorescence data from the fibres in the control samples
were used to produce linear regression models for the relationships
between levels of Complex I and porin, and between Complex IV and
porin. The regression findings were then used to predict the expected
levels of Complex I and IV per fibre among study participants based on
the fibres' measured porin levels. The measured values in Complex I and
IV were then expressed as Z-scores. Porin values in the fibres of study
participants were also expressed as Z-scores, that is, expressed relative
to the values seen in the control samples (which were defined as having
a mean of 0 and standard deviation (SD) of 1). The percentages of
deficient fibres (range) were calculated as the sum of the intermediate
positive, intermediate negative, and negative fibres for each sample.
Deficient fibres were defined as those deviating from the normal ex-
pected expression (Complex I and Complex IV, porin) in the controls.
2.6. Statistics
Descriptive statistical analyses were calculated for variables of in-
terest in SPSS version 24.
3. Results
3.1. Participants
Of the 13 participants approached, nine consented and all com-
pleted the entire assessments. Reasons for non-participation were
medically unwell or not interested in research. The mean age of parti-
cipants was 79.9 (± 6.2) years; two were female; and mean disease
duration was 3.3 years (range 1.6–5.6) (Table 1). Two (22.2%) were
diagnosed with PDD, 22.2% had PD-MCI and five were cognitively
normal.
3.2. Feasibility, acceptability and overall findings for muscle mitochondrial
function and content
It was possible to attempt the MRS protocol in all, with all but one
participant achieving sufficient depletion of phosphocreatine by ex-
ercising. Mean τ1/2 PCr was 37.8 (7.6) seconds, which was slightly
higher than previously seen by our group in healthy 85 year-olds
(Dodds et al., 2018), but not significantly so. It was also possible to
obtain muscle tissue in all participants, with no complications noted at
the follow-up visit. Analysis of mitochondrial respiratory chain levels
demonstrated a small amount of Complex I (0.15–4.59% of fibres; mean
0.49 (SD 0.98) Z-score) and Complex IV (0–3.79% of fibres; mean
−0.12 (SD 0.81) Z-score) deficiency (Table 1, Fig. 1.). The majority of
patients also showed a reduction in mitochondrial mass (0–89.3% of
fibres; mean porin Z-score of 0.90 (SD 1.28)), with over half (5 out of 9)
patients having> 20% of fibres classified as low porin (Table 1,
Fig. 1.).
3.3. Sarcopenia status
Six participants had weak handgrip and/or chair rise (probable
sarcopenia), with two of these also having low SMI (confirmed sarco-
penia). Of the two with confirmed sarcopenia, one also had a gait speed
≤0.8 m/s, indicating severe sarcopenia. Those with probable/con-
firmed sarcopenia tended to be older (81.8 vs. 76.1 years), with greater
motor scores (MDS-UPDRS 3 27.2 vs. 21.0), lower cognitive scores
(MMSE 26.7 vs. 28.7; MoCA 21.5 vs. 25), and lower BMI (23.7 vs. 27.0)
than those without sarcopenia. Four of the six with probable/confirmed
sarcopenia had PD-MCI or PDD, whereas all participants with normal
muscle function had normal cognition. PD duration (3.3 vs. 3.2 years),
LEDD (438.8 vs. 421.7 mg/day), SF36 physical functioning (72.5 vs. 75)
and SF36 general health (64.2 vs. 60) were similar in those with and
without sarcopenia, respectively. All but one participant had usable
accelerometry data. Self-reported activity scores for aerobic (4.5 vs. 5)
and strength and flexibility (0.3 vs. 0.6) were similar across the groups;
a finding that was corroborated by objective Axivity measures (mean
steps per day 11,632 vs. 12,250; walk time per day 155.9 vs.
164.4 min). With respect to mitochondrial function and content in
those with and without sarcopenia, Z-scores for Complex I (0.20 vs.
1.06, respectively) and Complex IV (−0.24 vs. 0.12, respectively) were
greater in those with normal muscle function. Z-scores for porin (−0.97
vs. −0.75, respectively) were broadly analogous, although in the sar-
copenia group two participants had Z-scores greater than three SD
below normal. Recovery times from 31P-MRS scanning were compar-
able across the groups (τ1/2 PCr 36.9 vs. 40.7 s).
4. Discussion
This study represents the first comprehensive muscle phenotyping
of participants with PD across a spectrum of cognition, and demon-
strates that phosphorous magnetic resonance spectroscopy and muscle
biopsy is feasible and safe in older patients with and without cognitive
impairment. In this small cohort of participants from secondary care,
sarcopenia was common and there was some evidence of reduced
skeletal muscle mitochondrial content. The study of sarcopenia in long-
term conditions such as PD is paramount to understanding potential
cellular and molecular mechanisms of sarcopenia, to enable better di-
rection of future interventions.
In keeping with recent prevalence studies of sarcopenia in PD (Lima
et al., 2020; Peball et al., 2019; Vetrano et al., 2018; Yazar et al., 2018),
probable/confirmed sarcopenia was a frequent occurrence and was
present in two-thirds of participants. Although a minority of studies
have demonstrated lower prevalence (Barichella et al., 2016; Tan et al.,
2018), sarcopenia diagnosis is dependent on definition used, with one
study in PD demonstrating little agreement among different criteria
evaluated (Vetrano et al., 2018). Our study is one of the few studies to
utilize the new EWGSOP2 guidelines to identify sarcopenia within
neurodegenerative disease (Lima et al., 2020). Further novelty is re-
flected in the breadth of cognitive status seen in our participants, de-
monstrating the feasibility of deep phenotyping even in those with early
PDD. All of those with either PD-MCI or PDD had probable/confirmed
sarcopenia, with one of the PDD participants reaching “severe” status.
Caution is required, however, in interpreting these results, due to the
small numbers within the subgroups. To date there has been a paucity
of work on the interrelationship between dementia and sarcopenia,
despite potential shared underlying mechanisms such as neuroin-
flammation (Drey et al., 2017). This is particularly evident in Lewy
body dementia, with no studies to date examining muscle function.
To our knowledge, this is the first study of 31P-MRS of the gastro-
cnemius and soleus muscles in older PD participants. We have de-
monstrated that this is feasible and well tolerated, with all but one
participant attaining sufficient depletion of phosphocreatine during
exercise. Two historic studies in PD utilised MRS of the forearm with
conflicting results regarding muscle energetics (Taylor et al., 1994;
Penn et al., 1995), although mean age was much younger, and sarco-
penia was not the focus in either study. The mean τ1/2 PCr in our
sample was largely in keeping with preserved mitochondrial oxidative
capacity in calf muscle, although slightly longer than seen in a small
sample aged 70–83 years (32 s) (Taylor et al., 1997) and healthy
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85 year-olds (35.6 s) (Dodds et al., 2018). It is noteworthy that two of
the three participants with longer (> 44 s) τ1/2 PCr values had sarco-
penia. A possible explanation for the largely normal values seen in our
study, despite high prevalence of sarcopenia, is the subjective and ob-
jective evidence of engagement in physical activity (average steps per
day>10,000), which demonstrably improves mitochondrial capacity
in non-PD patients (Distefano et al., 2018).
In keeping with previous work from our group in community-
dwelling older adults, primarily MRC positive fibres were seen on
quadruple immunofluorescence (Z-score ≥ −3) (Dodds et al., 2018;
Rygiel et al., 2017). Complex I and IV deficient fibres were present
at< 5% in all patients, which is comparable to previous findings in
aged muscle (Brierley et al., 1998). Mitochondrial mass (i.e. porin as a
marker) was also low in the majority of patients. Although this is ex-
pected in aging, the degree of mitochondrial depletion observed here
was slightly higher than previously reported, including in healthy
85 year-olds (Dodds et al., 2018). All participants agreed to undergo
muscle biopsy, which was well tolerated with no complications re-
ported.
4.1. Study strengths and limitations
Strengths of this work include the successful recruitment rate of this
detailed study, including muscle phenotyping and sarcopenia status
across a range of cognition in participants with PD. Our recent study of
a healthy 85-year-old group provided a comparison to ensure the mi-
tochondrial changes were not solely an effect of age (Dodds et al.,
2018). Limitations include the small sample size, precluding the ana-
lysis of associations between mitochondrial function and measures of
sarcopenia, cognitive assessments or disease severity. The inclusion of
chair rise as a measure of low strength may be confounded by brady-
kinesia and rigidity seen in PD; although this was minimized by en-
suring participants were assessed in their “on” state.
In conclusion, sarcopenia was common in a small cohort of PD
participants with MCI and PDD, and was associated with possible
changes in mitochondrial content. Detailed muscle phenotyping was
feasible and well tolerated, and provides potential evidence of the
mechanisms that may underpin sarcopenia in this neurodegenerative
disease.
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